Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

101-120 of 847 trials

Chronic Hypoparathyroidism: Eneboparatide (AZP-3601)

We are studying a new medication to see if it helps people with chronic hypoparathyroidism manage their calcium levels and improve their physical symptoms. This trial compares the new treatment to a placebo to assess its effectiveness.

Hypoparathyroidism6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Partially RemoteEndocrinology

Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

Fabry's Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyPediatrics

Advanced Melanoma: Lifileucel with Pembrolizumab

We are investigating whether a new treatment combining lifileucel with pembrolizumab is more effective than pembrolizumab alone for patients with untreated, advanced melanoma. The study aims to assess both effectiveness and safety.

MelanomaConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementDermatologyOncology

Mucopolysaccharidosis Type II: JR-141 Treatment Study

We are investigating the long-term effects of JR-141 on symptoms of Hunter Syndrome. This study will help us understand its safety and effectiveness for patients with this condition.

Mucopolysaccharidosis IIHunter Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementInternal MedicineNeurologyPediatrics

Vedolizumab for Kids with Ulcerative Colitis or Crohn’s Disease

We are studying a new injection form of Vedolizumab for children with moderate to severe ulcerative colitis or Crohn’s disease. The goal is to learn about its safety and how it works in the body after initial treatment.

Crohn's DiseaseUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Systemic Sclerosis-Associated Lung Disease: Belimumab Study

We are testing whether belimumab can improve lung function and reduce skin thickening in adults with systemic sclerosis-related lung disease. This study compares its effects to a placebo alongside standard treatment.

Systemic Sclerosis Associated Interstitial Lung Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementPulmonologyRheumatology

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Tenosynovial Giant Cell Tumor: Study of ABSK021

We are investigating a new treatment, ABSK021, for patients with Tenosynovial Giant Cell Tumor to see if it is safe and effective compared to a placebo. The study will also assess how it affects tumor size and patient mobility.

Tenosynovial Giant Cell Tumor6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteOncology

Mitapivat for Erythrocyte Membranopathies

We are studying the safety and effects of mitapivat in adults with erythrocyte membranopathies. This includes looking at hemoglobin levels and how it may help with symptoms.

Erythrocyte Membranopathies>2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematology

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemotePulmonology

Daridorexant for Insomnia in Alzheimer's Patients

We are studying whether daridorexant can improve sleep quality in individuals with mild cognitive impairment and mild to moderate Alzheimer's disease. This trial aims to evaluate its effects on sleep duration, daytime functioning, and overall health.

Insomnia Disorder>2 yearsMonitoring phase (IV)6-10 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementNeurologyPsychiatry

Sjögren’s Syndrome: Deucravacitinib Study

We are testing a new medication, deucravacitinib, for adults with active Sjögren’s Syndrome to see if it improves symptoms better than a placebo. The study also looks at the safety and tolerability of this treatment.

Sjogren's Syndrome1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementRheumatology

Lung Cancer Treatment: MK-2870 with Pembrolizumab

We are comparing a new combination treatment for metastatic non-small cell lung cancer to standard therapy. This study aims to see if the combination improves survival and quality of life for patients with high PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational MedicinesOncology

Chronic Lung Allograft Dysfunction: Belumosudil Tablets

We are testing belumosudil tablets to see if they improve lung function in adults with chronic lung allograft dysfunction after lung transplantation. The study will also look at how this treatment affects exercise capacity and overall health.

Lung Transplant Rejection6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Cholestatic Pruritus: Linerixibat Treatment Study

We are studying the long-term safety and tolerability of linerixibat for people with cholestatic pruritus due to primary biliary cholangitis. The trial also looks at how this treatment affects quality of life and itch relief.

Cholestatic PruritusPrimary Biliary Cholangitis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyHepatology

HER2-Positive Metastatic Cancer: Trastuzumab Emtansine Study

We are providing ongoing treatment with trastuzumab emtansine for patients who previously benefited from this therapy. The study aims to assess the safety of long-term use, either alone or with other cancer treatments.

Metastatic Breast CancerEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: Fazirsiran Treatment Study

We are investigating the long-term safety of fazirsiran for people with liver disease related to Alpha-1 Antitrypsin Deficiency. The study will also look at how this treatment affects liver health over time.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational MedicinesHepatologyPulmonology

Hereditary Angioedema: OCTA-C1-INH Treatment Study

We are studying a new intravenous treatment for people with hereditary angioedema to see if it effectively relieves symptoms during acute attacks. The trial includes adolescents and adults, and also looks at safety and quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteAllergologyHematology

Rare Ovarian Cancer: Abemaciclib and Letrozole Study

We are investigating the effects of a new treatment combining abemaciclib and letrozole for women with estrogen receptor positive rare ovarian cancer. The study aims to understand how well this treatment works and its impact on quality of life.

Adult-type Granulosa Cell TumorLow-Grade Serous Ovarian Cancer>2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Advanced Non-Small Cell Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have a specific genetic mutation. This trial compares the effects of the combination treatment to chemotherapy alone.

Non-Small Cell Lung Cancer6-12 monthsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncologyPulmonology

Search Clinical Trials in the European Union